Date: 2011-03-23
Type of information: R&D agreement
Compound:
Company: Sanofi-Aventis (France) The Vision Institute (France)
Therapeutic area: Ophtalmological diseases
Type agreement: R&D
Action mechanism:
Disease:
Details: Fovea Pharmaceuticals, Sanofi-Aventis’s ophthalmology division, and the Vision Institute (Institut de la Vision) have signed a cooperation agreement that aims to set up a privileged partnership between sanofi-aventis and the Vision Institute on the model of translational R&D and to strengthen the collaboration of sanofi-aventis with the bodies constituting the Vision Institute, such as the Pierre and Marie Curie University (UPMC), INSERM, the French National Institute of Health and Medical Research, and CNRS, the French National Center for Scientific Research. This research partnership will allow sanofi-aventis to further develop its platform dedicated to ophthalmology, by broadening the range of expertises in promising areas, in order to bring innovative solutions to patients where unmet therapeutic needs remain, particularly in retinal diseases. Under the terms of this 3-year agreement, sanofi-aventis will be given priority access to the technological platforms of the Vision Institute to conduct research activities and will support research and collaboration projects in particular in the area of regeneration of the optical nerve, vascular biology, inflammation and gene therapy in various eye tissues. Sanofi-aventis will be granted exclusive and worldwide rights to the results of the collaboration. In case of commercialization, sanofi-aventis would pay royalties to the members of the Vision Institute.
Financial terms:
Latest news:
